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Many staging systems of hepatocellular carcinoma (HCC) were established; however, there is no consensus on which is proper
in predicting prognosis. This study aims to evaluate various commonly used staging systems of HCC. Patients who underwent
surgery during 2001–2007 were included. All patient data were retrospectively staged using six staging systems, that are American
JointCommitteeonCancer(AJCC)Tumour-Node-Metastasis(TNM),Okudastaging,CanceroftheLiverItalianProgram(CLIP),
Barcelona Clinic Liver Cancer (BCLC), Chinese University Prognostic Index (CUPI), and Japan Integrated Staging (JIS). Child-
Pugh classiﬁcation was also evaluated. The staging systems were compared by mean of overall and disease-free survival. Total of
99 patient data were enrolled in the analyses. All staging systems except Okuda were signiﬁcant in determining overall survival in
univariate analyses. In multivariate analyses, TNM and Child-Pugh demonstrated better predictive power for overall survival. In
terms of disease-free survival, univariate analyses revealed that TNM, CLIP, BCLC, CUPI, and JIS were signiﬁcant, and TNM was
the best predictive staging system in multivariate analyses. In our study, TNM and Child-Pugh are the representative systems in
predicting survival of HCC patients who undergo surgical resection. Moreover, they are practical and easily assessable in clinical
practice.
1.Background
Hepatocellular carcinoma (HCC) is the most common
primary malignancy of liver and one of the most common
malignancies especially in Eastern and Southeastern Asia.
ThemostimportantriskfactorsofHCCarechronichepatitis
B, C and cirrhosis.
In malignancy diseases, staging system is important
because it deﬁnes prognosis and is a guiding tool for
treatment options and also a research tool for comparison
between diﬀerent groups and trials [1]. American Joint
Committee on Cancer (AJCC) uses tumour-node-metastasis
(TNM) system as staging system for many malignancy
diseases to predict prognosis [2]. Nevertheless, in HCC,
AJCC/TNM system fails to stratify patients adequately with
respect to prognosis because TNM system evaluates only
tumour extension. Since the remnant liver function is
another important factor to prognosis of patients with HCC
beside tumourburden;therefore,the staging system forHCC
should include these both factors [3].
Staging systems that include liver function status were
ﬁrst proposed by Okuda et al. in 1985 based on study
of 850 HCC patients [4]. This Okuda staging system was
consisted of tumour load, ascites, albumin, and bilirubin. It
was accepted and used widely as an improved classiﬁcation
system for HCC. Since the introduction of this staging
system about two decades ago, when most HCC cases were
diagnosedin theadvanced stage,therewas muchprogression
in diagnostic and therapeutic tools for patients with HCC.
Most patients are now diagnosed in less extensive disease.
TheOkudastagingsystemdoesnotproperlyidentifypatients
who may be suitable for certain therapeutic interventions
[5]. Recently many staging systems for HCC were proposed,
they were known as newer scores. In 1998, the Cancer of
the Liver Italian Program (CLIP) investigators proposed the
CLIPscore thatisbased onChild-Pughgrading, distribution
of tumour(s), alpha-fetoprotein (AFP) level, and portal
vein thrombosis [6]. This scoring system was validated
prospectively in 196 patients and showed greater predictive
power than Okudastaging system [7]. In1999,theBarcelona2 HPB Surgery
Clinic Liver Cancer (BCLC) staging classiﬁcation for HCC
wasproposed byLlovetet al. in theaim ofdeﬁning prognosis
and treatment strategies [8]. It stratiﬁed tumours into four
risk groups and proposed diﬀerent planning of treatment
for each group. Recently, it was validated prospectively in
195 patients in Italy and demonstrated a better prognostic
ability than AJCC/TNM 2002 system in surgical patients [3].
In Asia, there were also some proposed staging systems as
they claimed that the natural history might be diﬀerent in
diﬀerent places around the world. The Chinese University
Prognostic Index (CUPI) for HCC was identiﬁed in Hong
Kong on the basis of a cohort of 926 Chinese patients in
2002 [9]. It combines the conventional TNM system with
some factors of liver function and tumour load. The authors
reported that the CUPI was better than TNM, Okuda, and
CLIPstagingsysteminpredictingsurvival.In2003,theJapan
Integrated Staging (JIS) score was proposed by Kudo et al.
[10]. It is based on new adapted TNM system proposed by
the Liver Cancer Study Group of Japan (LCSGJ) and Child-
Pugh grading. In this study, it showed that JIS was superior
to CLIP score in selecting the best prognosis patients group.
Though many staging systems for HCC were introduced
around the world, there is no consensus on which the best
in predicting prognosis and selecting patients into diﬀerent
treatment planning [1]. The aim of thisstudy was toevaluate
and compare the various commonly used staging systems for
HCC in term of predicting prognosis of the Thai patients
who underwent surgical resection.
2.Materialsand Methods
This study was retrospective cohort study. Patients who
were admitted for surgical resection in Department of
Surgery Siriraj Hospital during January 2001 and June 2007
were included in the study. Medical records were reviewed.
DiagnosisofHCCwasconﬁrmedbyhistopathologicalreport
or by clinical and radiological ﬁnding that serum alpha-
feto protein (AFP) level more than 200ng/dl associated with
radiological investigation is suggestive of HCC. The patients
withincompleteinformation afterreviewing medicalrecords
and who were lost to followup were also excluded from the
study.
The data was reviewed and collected in terms of geo-
graphic data including ECOG performance status [11], clin-
ical presentation, tumour characteristics both pathological
and radiological, cause and severity of cirrhosis, biochemical
and immunological data (e.g., viral hepatitis status), and
operative details.
All patient data were retrospectively staged using the
six staging systems, that is, American Joint Committee
on Cancer (AJCC) tumour-node-metastasis (TNM) 2002
system, Okuda staging system, Cancer of the Liver Italian
Program (CLIP) scoring system, Barcelona Clinic Liver Can-
cer (BCLC) staging system, Chinese University Prognostic
Index (CUPI), and Japan Integrated Staging (JIS). Child-
Pugh classiﬁcation for cirrhosis was also evaluated.
All patients were followed up to December 2007. Last
status at followup, recurrence, and mortality were recorded.
Disease-free survival was calculated from date of operation
to date of recurrence. Overall survival was calculated from
date of diagnosis to date of death.
In data analysis, comparison between two groups of
continuous data was analysed using the unpaired t-test and
the Mann-Whitney U test. Relationship between nominal
and ordinal data was analysed using the Chi-squared test
or the Fisher’s exact test. Univariate survival analyses of
each staging system were calculated using the Kaplan-Meier
method and compared by means of the log rank test. A
stratiﬁed Cox proportional hazard regression model was
used for multivariate analyses. Statistical signiﬁcance is
deﬁnedasa P valueof ≤0.05.The SPSSversion10.0software
package was used for this statistical analysis.
3.Results
Total of 181 patient data were reviewed, and 82 patients
of these were excluded. There were incomplete data for
evaluation in 15 patients, and 67 patients were lost to
followup. Therefore 99patientswere enrolled in theanalyses.
Mean age of the patients was 57.6 years with range from
twenty-three to eighty-one years. There were male more
than female patients at the ratio about three to one (M:F=
75:24).
In terms of aetiology of cirrhosis, there were chronic
hepatitis B 47 patients (47.5%), chronic hepatitis C 11
patients (11.1%), chronic hepatitis B and C coinfection
1 patient (1.0%), alcoholic cirrhosis 4 patients (4.0%),
cryptogenic cirrhosis 1 patient (1.0%), and unspeciﬁed 25
patients (25.2%).
In surgical resection type, there were right hepate-
ctomy 17 patients (17.2%), left hepatectomy 9 patients
(9.1%), anatomical segmental resection 22 patients (22.2%),
nonanatomical wedge resection 38 patients (38.4%), and
other operations (e.g., liver biopsy, liver packing) 13 patients
(13.1%).Thirtydayspostoperativemortalitywas5.1percent.
There were three patients died from sepsis, one from rup-
tured HCC, and one from postoperative bleeding.Follow-up
time was up to one hundred and ten months, with mean at
26 months.
The patient data was categorized using six staging
systems and also Child-Pugh classiﬁcation, as described in
Figure 1.Therewere 65patientsinOkudastage1,34patients
in Okuda stage 2, and none in Okuda stage 3. Thirty-ﬁve
patients had CLIP score of 0, 35 patients had CLIP score of
1, 22 patients had CLIP score of 2, and 5 patients had CLIP
score of4. Forty-four patientswere categorized in BCLC A1–
A4, 14 patients in BCLC B, 41 patients in BCLC C, and none
in BCLC D. In TNM staging system, there were 37 patients
in stage I, 26 patients in stage II, 19 patients in stage IIIa,
10 patients in stage IIIb, 2 patients in stage IIIc, and none
in stage IV. In CUPI staging system, 36 patients got score of
−7, 17 patients got −5, 6 patients got −4, 14 patients got
−3, 5 patients got −2, 7 patients got −1, 6 patients got 0,
1 patient got 1, 4 patients got 2, and 3 patients got score of
5. Seven patients had JIS 0, 30 patients had JIS 1, 37 patients
had JIS 2, 23 patients had JIS 3, and 2 patients had JIS 4.HPB Surgery 3
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Figure 1: Patients data categorized using six staging systems and
Child-Pugh classiﬁcation.
Table 1: Univariate analyses of overall survival data.
Staging system P value
Okuda 0.1844
CLIP 0.0213
BCLC 0.0117
TNM 0.0148
CUPI 0.0093
JIS 0.0070
Child-Pugh 0.0039
Table 2: Multivariate analyses of overall survival data.
Staging system Multivariate analysis
Hazard ratio 95% CI P value
Okuda — — n/a
CLIP — — 0.517
BCLC — — 0.323
TNM 2.702 1.168–6.251 0.020
CUPI — — 0.182
JIS — — 0.253
Child-Pugh 2.238 1.132–4.424 0.021
Sixty-nine patients had cirrhosis Child A, 30 patients had
cirrhosis Child B, and none had Child C.
In overall survival, all of the staging systems except
Okuda staging system were signiﬁcant in the univariate
analyses (Table 1) and enrolled in multivariate analysis.
In multivariate analyses, TNM staging system and Child-
Pugh classiﬁcation demonstrated better predictive power
for overall survival comparing with CLIP, BCLC, CUPI, JIS
systemswithPvalueof0.020and0.021,respectively(Table 2,
Figure 2).
In terms of disease-free survival, univariate analyses
demonstrated that CLIP, BCLC, TNM, CUPI, JIS staging
were signiﬁcant with P value of 0.0289, 0.0003, 0.0001,
0.0128, 0.0157, respectively (Table 3). In multivariate analy-
ses, TNM was shown to be the best predictive staging system
with P value of 0.001 (Table 4, Figure 3).
Table 3: Univariate analyses of disease-free survival data.
Staging system P value
Okuda 0.8569
CLIP 0.0289
BCLC 0.0003
TNM 0.0001
CUPI 0.0128
JIS 0.0157
Child-Pugh 0.5728
Table 4: Multivariate analyses of disease-free survival data.
Staging system Multivariate analysis
Hazard ratio 95% CI P value
Okuda — — n/a
CLIP — — 0.053
BCLC — — 0.789
TNM 4.193 1.950–9.015 0.001
CUPI — — 0.088
JIS — — 0.160
Child-Pugh — — n/a
4.Discussion
Staging system is very important in every malignant disease.
It does not only predict prognosis but also provides plan
of management. It was an important tool to categorize
and compare patients in research study. Most of all, there
was only one commonly used staging system for each
malignancy, but not in HCC. HCC is one of the distinctive
malignancies because it has two pathological changes in one
disease. Firstly, it is the tumour change from hepatocytes
itself and the other is cirrhosis, chronic inﬂammation, and
ﬁbrotic change of liver parenchyma. Most of HCCs are
arising on topof cirrhosis. Cirrhosis and liverfunction status
are very important factors in determining plan of treatment
especially surgical resection.
Nowadays, there are many staging systems proposed
worldwide. Some are simple and easy to remember such
as Okuda staging system. Some are more complicated but
claimed to have more predictive power. There are many
publications comparing these staging systems, but until now
there is no consensus on which is the best prognostic staging
system for HCC [12–17]. This study would be the ﬁrst
study about staging systems of HCC in Thai patients who
underwent surgical resection.
In general, staging systems of HCC have divided into 2
categories, clinical staging system and pathological staging
system. The clinical staging systems usually deﬁne patients
initially at pretreatment state and include clinical, radio-
logical, and laboratory data. Nevertheless, they would not
include pathological factors that would be obtained after
surgical resection. The pathological staging systems almost
always include data from pathological reports that have to
be conﬁrmed after surgery, and they will provide more
informative data in terms of predicting survival. However,4 HPB Surgery
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Figure 2: Kaplan-Meier survival curves of overall survival.
they can only be applied to patients who have undergone
surgery [18]. Thus in surgical patients, staging systems that
includedata from pathological report should comprise more
discriminating power to predict survival.
The applicability of staging systems of HCC is also
dependent on the selection of treatment. The predictive
power may be diﬀerent in each group of patients. For exam-
ple, the best staging system for HCC patient who underwent
surgery might not be suitable for patients with advanced
diseasewhoonlyreceivedsupportivecare.Inacohortof2010
Taiwanese patients, the Tokyo staging system was the best in
predictingsurvival forpatientsreceivingsurgicalresectionor
transarterial chemoembolization while CLIP scoring system
was the most suitable in predicting survival in HCC patients
receiving chemotherapy or supportive care [14]. In patients
who underwent surgical resection, there are many studiesHPB Surgery 5
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Figure 3: Kaplan-Meier survival curves of disease-free survival.
showing that the most suitable staging system for surgical
HCC patients was TNM [15, 19], CLIP [20, 21], or JIS [22].
Furthermore, diﬀerent staging systems have diﬀerent
predictive power for HCC patient in diﬀerent area of the
world, roughly the East and the West. That couldbe from the
diﬀerence in tumour biology and also the aetiology of liver
cirrhosis. In Eastern countries, studies from China, Korea,
and Taiwan demonstrated that either TNM [15, 19, 23]o r
CLIP [20, 24] had better predictive power than others, while
many studies from Japan favoured JIS as the best staging
system [22, 25, 26]. In contrary, most studies from Western
countries suggested that either BCLC [3, 27, 28]o rC L I P
[29, 30] had superior discriminatory power.
Most of patients in this study were distributed in earlier
stage in both tumour biology and liver parenchymal or
cirrhotic change. There was no patient in most advanced6 HPB Surgery
stage such as in Okuda stage 3, TNM stage IV, and BCLC
stage D. This result was caused by the selection of study
population which includedthe patients who were candidates
for surgery and certainly these patients would have early
stage of disease. Patients who had advanced disease were not
suitable for surgery. The selection of such patients cause the
limitation of the application of the results of this study to
only the surgical candidates.
In overall survival, the most predictive staging systems
in this study are AJCC/TNM staging system and Child-
Pughclassiﬁcation.AJCC/TNMstaging systemcontains only
tumour factor and does not include liver function status. It
has the best predictive power in both overall survival and
recurrence. On the other hand, Child-Pugh classiﬁcation is
a good prognostic factor of liver function in cirrhosis and
used widely. It can also predict overall survival, but not
recurrence. When combined together, these two systems are
still the best systems in predicting survival of patients with
HCC especially in the group of the surgical candidates. They
are also practical, easy to remember and to use. This study
is the one among other studies that emphasizes pathological
staging system for patients under surgery.
AJCC/TNM staging system was also validated in patients
who underwent liver transplantation for HCC. Vauthey
et al. conducted multicenter study in US and Europe
comparing many staging systems, including, AJCC/TNM,
CLIP,JIS,andBCLCintermsofpredictingsurvival afterliver
transplantation for HCC. The AJCC/TNM staging system
had the best stratiﬁcation of prognosis for patients who
underwent liver transplantation. Combining with previous
studies in patients who underwent surgical resection, the
authors proposed that AJCC/TNM staging system provided
a uniform evaluation of prognosis in HCC patients who
underwent surgery including both surgical resection and
livertransplantation [31].The American-Hepato-Pancreato-
Biliary Association (APHPBA) and the AJCC Consensus
Conference also recommended the use of the sixth edition of
AJCC/TNMstaging system forsurgical patientsafter surgical
resection and liver transplantation [18].
There are still some drawbacks of AJCC/TNM staging
system in the very early stage of HCC. Even in early HCC
such as tumour size less than 5cm, no major vascular
invasion, node negative, no metastasis, that is, T1N0M0,
there were still some factors that aﬀect survival outcome of
thepatients.Nathanetal.studiedacohortofearlystageHCC
patients and found tumour size, even in tumour size ≤5cm,
multifocality, and microvascular invasion as important fac-
tors that inﬂuenced the patients’ survival. They proposed
new staging system called Early HCC prognostic score that
was summarized from each point for each factor [32]. This
score was validated in multicenter trial compared to many
staging systems including Okuda, International Hepato-
Pancreato-Biliary Association(IHPBA)stagingsystem,CLIP,
BCLC, JIS, and AJCC/TNM. Early HCC prognostic score
and AJCC/TNM showed good stratiﬁcation of patients who
underwent surgical resection or liver transplantation, while
others did not. In fact, early HCC prognostic score was
superior to AJCC/TNM for predicting survival of early HCC
patients [33].
In conclusion, though there are many new staging
systems, TNM staging system and Child-Pugh classiﬁcation
are the proposed prognostic staging systems in determining
survival of postsurgical resection HCC patients in our study.
Although the result suggests using these two systems com-
bined together as a staging system in HCC especially in the
surgical candidate patients because they are practical, easily
assessable, and simple applications in the clinical practice,
the authors consider that some other staging systems such
as Tokyo staging system and early HCC prognostic score
wouldhaveamajorroleinpredictingthesurvival.Therefore,
further study should be performed in the large population
including the nonsurgical patients and should put on some
newscoringsystems suchasIHPBAorEarlyHCCprognostic
scoring systems in the analysis.
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